These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933 [TBL] [Abstract][Full Text] [Related]
11. Differential expression of lipoprotein lipase gene in tissues of the rat model with visceral obesity and postprandial hyperlipidemia. Hikita M; Bujo H; Yamazaki K; Taira K; Takahashi K; Kobayashi J; Saito Y Biochem Biophys Res Commun; 2000 Oct; 277(2):423-9. PubMed ID: 11032739 [TBL] [Abstract][Full Text] [Related]
12. [Physiopathology of primary hyperlipidemias]. Luc G; Turpin G; De Gennes JL Ann Med Interne (Paris); 1986; 137(2):155-66. PubMed ID: 3521430 [TBL] [Abstract][Full Text] [Related]
13. Low postheparin plasma hepatic lipase activity in familial type IIa hyperlipoproteinemia. Nikkilä EA; Huttunen JK; Ehnholm C Ann Clin Res; 1976 Feb; 8(1):63-7. PubMed ID: 180867 [TBL] [Abstract][Full Text] [Related]
14. Heritable, diet-induced hyperlipidemia in California mice (Peromyscus californicus) is due to increased hepatic secretion of very low density lipoprotein triacylglycerol. Krugner-Higby L; Shelness GS; Holler A Comp Med; 2006 Dec; 56(6):468-75. PubMed ID: 17219776 [TBL] [Abstract][Full Text] [Related]
15. [Activity of the clearing factor in the pathogenesis of hyperlipidemia in experimental nephrotic syndrome]. Nikiforova NV Biull Eksp Biol Med; 1966 Dec; 62(12):29-32. PubMed ID: 6005418 [No Abstract] [Full Text] [Related]
17. Hyperlipidemia in acute lymphoblastic leukemia. Blackett PR; Koren E; Blackstock R; Downs D; Wang CS Ann Clin Lab Sci; 1984; 14(2):123-9. PubMed ID: 6585175 [TBL] [Abstract][Full Text] [Related]
18. [Pathogenesis of hyperlipoproteinemia in kidney diseases]. Mordasini R; Greten H Verh Dtsch Ges Inn Med; 1978; (84):1284-7. PubMed ID: 741951 [No Abstract] [Full Text] [Related]
19. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Niho N; Takahashi M; Kitamura T; Shoji Y; Itoh M; Noda T; Sugimura T; Wakabayashi K Cancer Res; 2003 Sep; 63(18):6090-5. PubMed ID: 14522940 [TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis of hyperlipoproteinemias]. Müller G Z Gesamte Inn Med; 1974 Jun; 29(12):469-76. PubMed ID: 4368206 [No Abstract] [Full Text] [Related] [Next] [New Search]